Global Paresthesia Treatment Market Size, Share, Forecast Report, 2020-2027

Paresthesia is an abnormal sensation of the skin such as numbness, burning, pricking, and many other. On the basis of severity, they are acute or chronic. Some of the major causes of for the diseases are vitamin deficiency, hyperventilation syndrome, or by the use of anesthesia. The global paresthesia treatment market is majorly driven by increasing prevalence of the paresthesia, changing lifestyle and poor diet. Furthermore, development in the healthcare expenditure, the government support for the research & development for new and better treatment have fuelled the market growth. However, lack of effectiveness and unavailability of precise treatment may hinder the market growth over the forecasted period.
Segmentation

The global paresthesia treatment market is segmented on the basis of types, treatments, and end users. On the basis of types, the market is segmented into acute paresthesia, chronic paresthesia. On the basis of treatment, the market is segmented into immunosuppressant, anticonvulsants, topical creams, antivirals, and others. Immunosuppressant is further classified into prednisone, intravenous gamma globulin, and others. Topical creams are further classified into lidocaine, prilocaine, and other. On the basis of end users the market is segmented into hospitals, clinics, diagnosis centers, and others.
Key players

Some of the major players in the global paresthesia treatment market are Medtronic (UK), Omron Healthcare, Inc. (US), Boston Scientific Corporation (US), Stimwave LLC, (US), Nevro Corp. (US), Cyberonics, Inc. (US), EnteroMedics Inc. (US), St. Jude Medical, LLC. (US), Bio-Medical Research Ltd. (UK), Baxter (US), Stryker (US), GlaxoSmithKline plc.(UK).